导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -4.03% | 1847/2813 |
| 近一周 | -2.59% | 1467/3199 |
| 近一月 | -1.98% | 656/3179 |
| 近一季 | -3.86% | 915/3051 |
| 近半年 | -8.05% | 1914/2892 |
| 近一年 | -7.21% | 1862/2611 |
| 近两年 | 39.00% | 1227/1896 |
| 近三年 | 19.81% | 895/1425 |
| 成立以来 | 36.14% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.30% 2229/4961 |
-1.68% 3360/5312 |
- - |
- - |
| 2025 | 15.65% 2522/4813 |
3.22% 1149/3635 |
8.98% 305/4076 |
5.01% 3623/4524 |
-2.09% 3086/4813 |
| 2024 | 16.45% 810/3463 |
4.56% 446/2808 |
-2.93% 1278/3014 |
13.59% 2154/3129 |
1.00% 1136/3463 |
| 2023 | -3.30% 634/2656 |
2.35% 1370/2280 |
2.49% 138/2385 |
-1.94% 604/2515 |
-5.99% 1582/2655 |
| 2022 | -13.13% 315/2207 |
-9.96% 371/1919 |
1.62% 1447/2016 |
-10.31% 380/2113 |
5.87% 421/2208 |
| 2021 | 12.39% 385/1822 |
3.89% 166/1255 |
8.97% 594/1330 |
-5.08% 775/1466 |
4.59% 324/1822 |
| 2020 | - - |
- - |
- - |
- - |
2.60% 980/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 华夏中证浙江国资创新发展ETF联接C VS. 长安沪深300非周期A(740101) |